Big News Regarding New MS Medications in Europe
I just wanted give you a brief update on some information which was released today. The European Medicines Agency's Committed on Medicinal Products for Human Use (CMPH) announced some approvals and rejections of applications to market certain medications in their neck of the world. The CMPH is the European version of the Food and Drug Agency (FDA) we have in the United States.
In short, the committe recommends Gilenya, rejects Movectro (cladribine), and rejects Fampyra (fampridine). I know that several of our members located in Europe and the Middle East have been asking about when Fampyra (known as Ampyra in the US) will be made available to them. This is disappointing news for MS patients who had wanted to try Fampyra.
I've detailed more of this news on my blog providing some relevant links. Rather than republish the post here, you can read European Medicines Agency recommends Gilenya (fingolimod), but rejects Fampyra (fampridine) and Movectro (cladribine).
I also just want to say thank you to all the members who provide such wonderful support to each other and to those who simply drop in to ask a question or two. Thank you for making MS HealthCentral a special place in the online MS community.